Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1980 Feb;41(2):277–284. doi: 10.1038/bjc.1980.40

Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro.

H Eichholtz, K R Trott
PMCID: PMC2010205  PMID: 7370167

Abstract

Chinese hamster, HeLa and HAK cells were treated with methotrexate (MTX) to determine the dependence of its effect on drug concentration and exposure time. With a broad range of survival curves for Chinese hamster cells, cell survival is an exponential function of exposure time and a power function of drug concentration. The data allow a mathematical description to be made of the interdependence of MTX concentration and drug exposure in relation to cell survival.

Full text

PDF
277

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berry R. J. Some observations on the combined effects of x-rays and methotrexate on human tumor cells in vitro with possible relevance to their most useful combination in radiotherapy. Am J Roentgenol Radium Ther Nucl Med. 1968 Mar;102(3):509–518. doi: 10.2214/ajr.102.3.509. [DOI] [PubMed] [Google Scholar]
  2. Borsa J., Whitmore G. F. Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res. 1969 Apr;29(4):737–744. [PubMed] [Google Scholar]
  3. Bruce W. R., Meeker B. E., Powers W. E., Valeriote F. A. Comparison of the dose- and timesurvival curves for normal hematopoietic and lymphoma colony-forming cells exposed to vinblastine, vincristine, arabinosylcytosine, and amethopterin. J Natl Cancer Inst. 1969 Jun;42(6):1015–1025. [PubMed] [Google Scholar]
  4. Creech R. H., Catalano R. B., Mastrangelo M. J., Engstrom P. F. An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer. Cancer. 1975 Apr;35(4):1101–1107. doi: 10.1002/1097-0142(197504)35:4<1101::aid-cncr2820350413>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  5. Divekar A. Y., Vaidya N. R., Braganca B. M. Active transport of aminopterin in Yoshida sarcoma cells. Biochim Biophys Acta. 1967;135(5):927–936. doi: 10.1016/0005-2736(67)90062-4. [DOI] [PubMed] [Google Scholar]
  6. Djerassi I., Rominger C. J., Kim J. S., Turchi J., Suvansri U., Hughes D. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer. 1972 Jul;30(1):22–30. doi: 10.1002/1097-0142(197207)30:1<22::aid-cncr2820300105>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  7. Goldman I. D., Lichtenstein N. S., Oliverio V. T. Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem. 1968 Oct 10;243(19):5007–5017. [PubMed] [Google Scholar]
  8. Hakala M. T. On the nature of permeability of sarcoma-180 cells to amethopterin in vitro. Biochim Biophys Acta. 1965 May 25;102(1):210–225. doi: 10.1016/0926-6585(65)90214-1. [DOI] [PubMed] [Google Scholar]
  9. Jackson R. C., Hart L. I., Harrap K. R. Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases. Cancer Res. 1976 Jun;36(6):1991–1997. [PubMed] [Google Scholar]
  10. Jaffe N., Frei E., 3rd, Traggis D., Watts H. Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases. Cancer. 1977 Jan;39(1):45–50. doi: 10.1002/1097-0142(197701)39:1<45::aid-cncr2820390109>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  11. Jaffe N. Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors. Cancer Chemother Rep. 1974 Mar-Apr;58(2):275–280. [PubMed] [Google Scholar]
  12. Pinedo H. M., Zaharko D. S., Bull J., Chabner B. A. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res. 1977 Feb;37(2):445–450. [PubMed] [Google Scholar]
  13. Sauer H., Wilmanns W. Adjuvante Chemotherapie des osteogenen Sarkoms mit High-Dose Methotrexat/Leucovorin: Biochemische Effekte auf die DNA-Synthese der Knochenmarkzellen. Blut. 1978 Jun 20;36(6):357–361. doi: 10.1007/BF01000594. [DOI] [PubMed] [Google Scholar]
  14. Sinclair W. K. Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science. 1965 Dec 24;150(3704):1729–1731. doi: 10.1126/science.150.3704.1729. [DOI] [PubMed] [Google Scholar]
  15. Weichselbaum R. R., Miller D., Pitman S. W., Kirkwood J. Initial adjuvant weekly high dose methotrexate with leucovorin rescue in advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1978 Jul-Aug;4(7-8):671–674. doi: 10.1016/0360-3016(78)90191-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES